Enlicitide

Short Description:

API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status 
Enlicitide 2407527-14-2 2027

 

[Indication] 

1. Hypercholesterolemia: As an adjunct to diet and exercise, to reduce low-density lipoprotein cholesterol (LDL-C) in adult patients with hypercholesterolemia.

2. Heterozygous familial hypercholesterolemia (HeFH): For the treatment of adult patients with heterozygous familial hypercholesterolemia (HeFH).


Product Detail

Product Tags


  • Previous:
  • Next:

  • Write your message here and send it to us